Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

R.J.W. van Kampen,B.L.T. Ramaekers,D.J.A. Lobbezoo,M. de Boer,M.W. Dercksen,F. van den Berkmortel,T.J. Smilde,A.J. van de Wouw,F.P.J. Peters,J.M.G. van Riel,N.A.J.B. Peters,V.C.G. Tjan-Heijnen,M.A. Joore

European Journal of Cancer（2017）

Cited 14|Views56

No score

Abstract

•Cost-effectiveness analyses regarding the addition of bevacizumab to taxane therapy based on real-world data was performed.•This is the first report on this topic using real-world data.•The study gives insight in the real-world cost-effectiveness of bevacizumab added to taxane chemotherapy.•The addition of bevacizumab is not cost-effective for HER2- negative MBC patients in daily practice in the Netherlands.

Translated text

Key words

Metastatic breast cancer,Bevacizumab,Cost-effectiveness analysis,Real-world,Trial based,Cost-benefit analysis

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined